Jason Luke, MD: Factors to Consider When Determining Treatments
What factors do you consider when determining treatments for patients like Sarah?
CASE: Metastatic Melanoma
Sarah is a 50-year-old Caucasian postal worker who presented to her primary care physician with multiple, skin-colored nodules and palpable lymph nodes. .
- A workup, biopsy, and mutation test was conducted, which revealed BRAF V600E mutation-positive melanoma that had metastasized to the lymph nodes, subcutaneous tissue, and right adrenal gland.
- ECOG performance status is 0 and her LDH levels are normal.
The patient was started on the combination of dabrafenib and trametinib. She experienced a durable complete response and has remained on therapy for 36 months.
Related Videos
Related Content
Dosing and Regimen Changes Promote Tolerability in Advanced Melanoma
March 14th 2024Article
During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed dosing considerations and toxicity when choosing combination treatment for patients with melanoma. This is the second of 2 articles based on this event.
Read More
